Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: A comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin

Journal of Clinical Pharmacology

Volumn 46, Issue 7, 2006, Pages 776-784

  Sandage, B ^a   Sabounjian, L ^a   Shipley, J ^a   Profy, A ^a   Lasseter, K ^b   Fox, L ^c   Harnett, M ^a  

^a Indevus Pharmaceuticals Inc   (United States)

^b SFBC International   (United States)

^c Discovery Labware   (United States)

Author keywords

Clinical trial; Digoxin; Interaction; Trospium chloride

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; MUSCARINIC RECEPTOR BLOCKING AGENT; TROSPIUM CHLORIDE;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BREAST DISEASE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG URINE LEVEL; DYSURIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY DISEASE; MALE; MEDIASTINUM DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NORMAL HUMAN; PREDICTION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STEADY STATE; SWINE; THORAX DISEASE;

ADOLESCENT; ADULT; ANIMALS; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; DIGOXIN; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; KIDNEY; LLC-PK1 CELLS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NORTROPANES; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SWINE; TRANSFECTION;

EID: 33745086570     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006289481     Document Type: Article

References (14)

1. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311-2315.
2. Abrams P, Wein AJ. Introduction: overactive bladder and its treatments. Urology. 2000;55:1-6.
3. Milson I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(suppl):S565-S573.
4. SANCTURA: trospium chloride 20 mg tablets [prescribing information]. East Brunswick, NJ: Esprit Pharmaceuticals Inc; 2004.
5. Hinderling PH, Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit. 1991:13:381-401.
6. de LKannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 1992:189:551-557.
7. Digoxin. MedicineNet.com. Available at: http://www.medicinenet. com/digoxin/article.htm.
8. LANOXICAPS drug label. GlaxoSmithKline. Available at: http://www.gsk.com/products/lanoxin_us.htm.
9. Hager WD, Fenster P, Maershon M, et al. Digoxin-quinidine interaction: pharmacokinetic evaluation. N Engl J Med. 1979;300: 1238-1241.
10. Pederson KE, Dorph-Pederson A, Hvidt S, Kilitgaard NA, Nielsen-Kudsk F. Digoxin-verapmil interaction. Clin Pharmacol Ther. 1981;30:311-316.
11. Rengelshausen J, Goggelmann C, Burhenne J, et al. Contribution if increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 2003;56:32-38.
12. Sandage BW, Profy AT, Fox L, Clark R. Trospium chloride does not inhibit digoxin transport by human P-glycoprotein in vitro [abstract]. J Clin Pharmacol. 2005;45:1084.
13. Schwartz JI, De Smet M, Larson PJ, et al. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 2001;41:107-112.
14. Bjornsson T, Callaghan J, Einolf H, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PHRMA) perspective. Drug Metab Dispos. 2003;21:815-832.